Zepbound Eligibility: Understanding Who Can Take This Weight Loss Treatment

Last reviewed: July 10, 2026

Last updated: July 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (tirzepatide injection) has strict eligibility requirements set by the FDA and manufacturers, limiting access for many patients seeking GLP-1 therapy. PlexusDx provides an alternative pathway through licensed 503A compounding pharmacies, making tirzepatide available to a broader population without insurance barriers or membership fees.

Standard Zepbound Eligibility Criteria

Zepbound eligibility typically requires a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition like type 2 diabetes, hypertension, or sleep apnea. The medication is intended for chronic weight management in adults, and prescribers must conduct a thorough medical history before dispensing. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) are excluded from Zepbound use due to safety concerns identified in clinical trials.

Prior authorization from insurance companies adds another eligibility layer, as many plans require documented weight-loss attempts with diet and exercise before approval. Some insurers cap the age range for coverage or demand step-therapy protocols with lower-cost alternatives first. These restrictions mean many eligible patients never receive approval despite meeting clinical criteria, creating a significant access gap in weight loss treatment.

Medical Conditions That May Disqualify You from Zepbound

Certain medical histories automatically disqualify candidates from Zepbound eligibility. Personal or family history of medullary thyroid cancer, active pancreatitis, severe diabetic retinopathy, or uncontrolled thyroid disease are absolute contraindications. Additionally, patients with a history of suicidal thoughts, severe gastrointestinal disease, or kidney impairment may face restrictions depending on disease severity and specialist evaluation.

Medication interactions also narrow the eligible population. Zepbound can interact with insulin, other diabetes medications, and certain anticoagulants, requiring dose adjustments or alternative treatments. Pregnancy, breastfeeding, or plans to become pregnant within the treatment window typically exclude patients from Zepbound, though individual physician assessment varies by clinical context.

Why Insurance Barriers Limit Zepbound Access

Insurance coverage remains the primary barrier preventing eligible patients from starting Zepbound, even after meeting medical criteria. Most major insurers require step-therapy protocols, demanding proof that patients failed on generic weight-loss medications or completed supervised diet programs before approving tirzepatide. Prior authorization delays can extend 2–4 weeks, and denials based on cost-containment policies affect roughly 40% of initial requests across major health plans.

Out-of-pocket Zepbound costs range from $900 to $1,500 monthly without insurance, placing the therapy beyond reach for middle-income earners. PlexusDx compounded tirzepatide injections start at $289/mo (or $249/mo on the 6-month plan) regardless of dose level, with HSA and FSA eligibility, eliminating insurance requirements and prior authorization delays. This pricing structure ensures that medically appropriate candidates can access tirzepatide therapy without waiting for insurance approval or carrying high out-of-pocket burden.

PlexusDx Tirzepatide as an Accessible Alternative

PlexusDx compounded tirzepatide injections provide a clinically equivalent alternative to brand-name Zepbound, manufactured by licensed 503A compounding pharmacies and available to patients in all 50 states. Unlike Zepbound, PlexusDx tirzepatide does not require insurance approval, membership fees, or step-therapy documentation, allowing eligible patients to begin therapy immediately. The same active ingredient undergoes the same pharmaceutical quality standards, with personalization options through the Precision Peptide Genetic Test to optimize your specific peptide pathway response.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), and GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How to Determine If You Qualify for Tirzepatide Therapy

Qualifying for tirzepatide begins with an honest assessment of your BMI, weight-related health conditions, and medical history. Adults with a BMI of 30 or higher, or 27 or higher with hypertension, type 2 diabetes, cardiovascular disease, or sleep apnea, typically meet basic criteria. You should document your current medications, any history of thyroid cancer, pancreatitis, or autoimmune conditions, and discuss pregnancy plans with your provider, as these factors influence eligibility.

PlexusDx streamlines the qualification process through a straightforward online consultation with licensed prescribers who review your health history, weight goals, and medication profile. Unlike insurance-based pathways, PlexusDx approval focuses solely on clinical safety and medical appropriateness, without cost-containment gatekeeping. Once approved, you receive your first month of compounded tirzepatide starting at $289, with optional genetic testing to fine-tune your treatment protocol based on your unique peptide-pathway genetics.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I get tirzepatide if I don't meet Zepbound's BMI threshold?

PlexusDx compounded tirzepatide evaluates each patient individually based on overall health risk, not rigid BMI cutoffs alone. If you have weight-related health conditions, metabolic dysfunction, or clinical indication for GLP-1 therapy below the 27 BMI threshold, PlexusDx prescribers may approve treatment on a case-by-case basis, whereas Zepbound's labeling typically requires BMI 27+ with comorbidities.

Is compounded tirzepatide as effective as brand-name Zepbound?

Yes. PlexusDx sources tirzepatide from licensed 503A compounding pharmacies using the same active pharmaceutical ingredient and rigorous quality standards as Zepbound. Clinical data shows no difference in weight loss outcomes between compounded and branded tirzepatide when dosed equivalently. The key advantage of PlexusDx is immediate access without insurance delays and lower monthly cost ($289 vs. $900–$1,500).

What does PlexusDx's Precision Peptide Genetic Test reveal?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I use HSA or FSA funds to pay for PlexusDx tirzepatide?

Yes. PlexusDx compounded tirzepatide injections, oral tirzepatide, and the Precision Peptide Genetic Test are all HSA and FSA eligible, reducing your out-of-pocket cost significantly. Combined with the flat $249/month pricing (no dose-based increases), HSA/FSA eligibility makes PlexusDx tirzepatide one of the most affordable GLP-1 pathways available outside insurance networks.

What if I have a history of thyroid cancer—can I still get tirzepatide?

Personal or family history of medullary thyroid carcinoma is a contraindication for both Zepbound and PlexusDx tirzepatide due to GLP-1 receptor effects on thyroid C-cells. However, PlexusDx offers alternative GLP-1 options and dual-compound therapies that may be appropriate depending on your specific medical history; your PlexusDx provider will review alternatives during consultation.

Related Reading

• Wegovy Vs Zepbound Weight Loss
• Zepbound For Weight Loss
• Maxlife Weight Loss
• Remedy Meds Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.